A Comparative Study of Attenuation of Hypertensive Response with Esmolol and Labetalol in Low doses in Orotracheal Intubation

Introduction: Esmolol and Labetalol, at low doses, were evaluated for attenuation of sympathomimetic reaction to laryngoscopy and intubation in this prospective, randomised, double-blind, comparative clinical study. Materials and Methods: This study involved 50 ASA 1 patients of either sex who were undergoing elective surgery under general anaesthesia. Prior to induction, patients were randomly assigned to one of two groups: group E got intravenous Esmolol (0.5 mg/kg) or group L received intravenous Labetalol (0.25 mg/kg), and hemodynamic parameters were monitored as per the procedure to determine stress response to laryngoscopy and intubation. Results: The demographic profiles of both research groups were similar. For statistical calculations, Instat version 3.10 was utilised. The data from the study was evaluated using statistical approaches such as mean and standard deviation. During laryngoscopy and intubation, esmolol (0.5 mg/kg) and Labetalol (0.25 mg/kg) significantly reduced the increase in heart rate, systolic blood pressure, and RPP. However, the difference was not statistically significant among the values for DBP and MAP. Conclusion: In lower doses, intravenous Labetalol (0.25 mg/kg) is a better agent than intravenous Esmolol (0.5 mg/kg) in attenuating the sympathomimetic reaction to laryngoscopy and intubation, according to our clinical trial. The typical dose of esmolol used to obtund intubation response is 2-4 mg/kg, whereas labetalol has been tested in all doses ranging from 0.25, 0.5, 0.75, and 1 mg/kg [1].